Table 1 Information about the EGFR-TKIs
From: Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
Drugs | Generation | Manufacturer | Launch Date | Reimbursement Date | Price negotiation |
|---|---|---|---|---|---|
Gefitinib (original) | First | AstraZeneca (UK) | Feb 2005 | Jan 2017 | ¥ 510.00 to ¥ 235.80 (Jul 2016) |
¥ 235.80 to ¥ 228.00 (Sep 2018) | |||||
Gefitinib (generic) | First | Qilu (China) | Feb 2017 | Jan 2017 | ¥ 176.00 to ¥ 158.40 (Apr 2018) |
¥ 158.40 to ¥ 80.00 (Apr 2019) | |||||
¥ 80.00 to ¥ 27.50 (Dec 2019) | |||||
Erlotinib | First | Roche (USA) | Mar 2007 | Jul 2017 | ¥ 601.24 to ¥ 195.00 (Jul 2017) |
¥ 195.00 to ¥ 182.25 (Jan 2019) | |||||
¥ 182.25 to ¥ 81.00 (Sep 2019) | |||||
Icotinib | First | Betta (China) | Aug 2011 | Jan 2017 | ¥ 429.28 to ¥ 396.43 (Jan 2015) |
¥ 396.43 to ¥ 199.86 (July 2016) | |||||
¥ 199.86 to ¥ 192.15 (Jan 2019) | |||||
Afatinib | Second | BoehringerIngelheim (German) | Feb 2017 | Jan 2019 | _______ |
Osimertinib | Third | BoehringerIngelheim (German) | Mar 2017 | Jan 2019 | _______ |